News

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company’s full-year revenue guidance of $3.10 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.

Professional consulting firm ICF International (NASDAQ:ICFI) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.4% year on year to $487.6 million. Its non-GAAP profit of $1.94 per share was 12.1% above analysts’ consensus estimates.

Temporary space provider WillScot (NASDAQ:WSC) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 4.7% year on year to $559.6 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.38 billion at the midpoint. Its non-GAAP profit of $0.24 per share was 11.1% below analysts’ consensus estimates.

Infrastructure consulting firm NV5 Global (NASDAQ:NVEE) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.1% year on year to $234 million. The company’s full-year revenue guidance of $1.04 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.17 per share was 8.9% below analysts’ consensus estimates.

Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.2% year on year to $1.01 billion. On the other hand, next quarter’s revenue guidance of $1.01 billion was less impressive, coming in 2% below analysts’ estimates. Its non-GAAP profit of $1.03 per share was 1.4% above analysts’ consensus estimates.

Scientific consulting firm Exponent (NASDAQ:EXPO) announced better-than-expected revenue in Q1 CY2025, with sales up 6% year on year to $145.5 million. On the other hand, next quarter’s revenue guidance of $130 million was less impressive, coming in 3.8% below analysts’ estimates. Its GAAP profit of $0.52 per share was 8% above analysts’ consensus estimates.

Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 12% year on year to $59.87 million. Guidance for next quarter’s revenue was optimistic at $62.5 million at the midpoint, 2.2% above analysts’ estimates. Its GAAP profit of $0.48 per share was 4.6% below analysts’ consensus estimates.